<DOC>
	<DOCNO>NCT01241708</DOCNO>
	<brief_summary>High dose chemotherapy stem cell transplantation commonplace treatment multiple myeloma . This treatment use chemotherapy drug call Melphalan use several thousand bone marrow transplant recipient worldwide similar disorder .</brief_summary>
	<brief_title>Tandem Auto Stem Cell Transplant With Melphalan Followed Melphalan Bortezomib Patients With Multiple Myeloma</brief_title>
	<detailed_description>Many patient multiple myeloma receive 2 stem cell transplantation within month part treatment . Usually drug Melphalan use transplant . Bortezomib drug use treat multiple myeloma use combination melphalan stem cell transplantation patient multiple myeloma . The purpose trial study effect 2 transplant , first use melphalan second use melphalan bortezomib . The trial aim find add Bortezomib second transplant increase chance stay remission longer .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Changed : Confirmed diagnosis multiple myeloma either DurieSalmon stage I , II , III ISS stage I , II III , less 12 month since initiation systemic therapy â‰¥8x106 CD34+cells/kg available cryopreservation aliquot appropriate tandem transplant Age : 1875 year time transplantation KPS 70100 % Recovery complication prior therapy Gender : There gender restriction Diagnosis multiple myeloma Chemotherapy radiotherapy within 8 day initiate treatment study Prior autologous allogeneic transplantation ( except enrol study ) Uncontrolled bacterial , viral , fungal parasitic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>